Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Geriatr Psychiatry Neurol ; 32(3): 152-163, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30885037

RESUMO

BACKGROUND: Alzheimer disease (AD) is the most common type of dementia which is becoming a primary problem in the present society, but it lacks effective treatment methods and means of AD. Tanshinone IIA (Tan IIA) has been reported to have neuroprotective effects to restrain the Aß25-35-mediated apoptosis. However, few studies try to understand how Aß1-42 affects hyperphosphorylation of tau and how Tan IIA regulates this process at the molecular level. METHODS: Fifty male Sprague-Dawley rats were randomly divided into 5 groups and infused through the lateral ventricle with Aß1-42 except the control group. Then the rats were treated with Tan IIA through intragastric administration for 4 weeks. After the ability of learning and memory being measured, histomorphological examination and Western blot were used to detect the possible mechanism in the AD-associated model rats. RESULTS: We observed that Aß1-42 infusion could induce spatial learning and memory deficits in rats. Simultaneously, Aß1-42 also could reduce the neuron in cornu ammonis 1 and dentate gyrus of hippocampus, as well as increase the levels of cleaved caspase 3, hyperphosphorylated tau at the sites Ser396, Ser404, and Thr205 with enhancing staining of black granules in brain. We also found that Aß1-42 could increase the activity of extracellular signal-regulated protein kinase (ERK) and glycogen synthase kinase-3ß (GSK-3ß). Meanwhile, these phenomena could be ameliorated when Tan IIA was used. CONCLUSION: We concluded that Tan IIA might have neuroprotective effect and improving learning and memory ability to be a viable candidate in AD therapy with mechanisms involving the ERK and GSK-3ß signal pathway.


Assuntos
Abietanos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Glicogênio Sintase Quinase 3 beta/efeitos dos fármacos , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Transtornos da Memória/tratamento farmacológico , Aprendizagem Espacial/efeitos dos fármacos , Abietanos/farmacologia , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Modelos Animais de Doenças , Humanos , Masculino , Ratos , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA